Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study

Archive ouverte : Article de revue

Darloy, Jean | Segaud, Nicolas | Salmon, Jean-Hugues | Eschard, Jean-Paul | Goeb, Vincent | Deprez, Xavier | Guyot, Marie-Helene | Houvenagel, Eric | Lecuyer, Nicolas | Marguerie, Laurent | Gally, Samuel | Pau, David | Idier, Isabelle | Baudens, Guy | Flipo, Rene-Marc

Edité par HAL CCSD ; Springer

International audience. IntroductionThe main objective of this work was to assess the maintenance of effectiveness of subcutaneous tocilizumab 6months after switching from intravenous to subcutaneous formulation in patients with rheumatoid arthritis(RA) in a real-world setting. Secondary objectives aimed to describe the characteristics of patients and disease, the effectiveness at 12months after switching, the therapeutic maintenance, and to search for predictive factors of switching.MethodsWe analyzed all the RA patients of the shared medical file RIC Nord de France, treated with tocilizumab, switching or not from intravenous to subcutaneous tocilizumab, between April 2015 and January 2016. The primary effectiveness endpoint was the proportion of patients remaining in their DAS28-ESR category remission/low disease activity (LDA) or moving to an inferior DAS28-ESR category at 6months. Since RoSwitch was an observational study, without randomization, a propensity score was built in a sensitivity analysis to balance on RA and patients' characteristics at inclusion between switching and no-switching groups.ResultsAn improvement of initial DAS28-ESR category or maintenance in DAS28-ESR remission/LDA at 6months was shown in 203 of the 285 patients with an evaluation for the primary criterion (71.2%, 95% CI [65.6-76.4%]) without differences between groups (73.3%, 95% CI [63.0-82.1%] vs. 70.3%, 95% CI [63.3-76.6%]). The RoSwitch study showed the maintenance of effectiveness at 6 and 12months. Similar therapeutic maintenance rates were observed for switch and no-switch patients. No clinical factor was associated with the switch in patients in remission/LDA at inclusion.ConclusionsThe RoSwitch study showed the maintenance of effectiveness at 6months in RA patients switching from intravenous (IV) to subcutaneous (SC) tocilizumab.FundingRoche SAS and Chugai Pharma France.

Consulter en ligne

Suggestions

Du même auteur

Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients...

Archive ouverte: Article de revue

Darloy, Jean | 2017

International audience

Actual Persistence of Abatacept in Rheumatoid Arthritis: Results of the Fre...

Archive ouverte: Article de revue

Salmon, Jean-Hugues | 2020

International audience. Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the ...

Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a ...

Archive ouverte: Article de revue

Letarouilly, Jean-Guillaume | 2021-06

International audience. Objectives: To evaluate the characteristics of patients (pts) with PsA treated by ustekinumab (UST) or secukinumab (SEK) and to compare real-world persistence of UST and SEK in PsA.Methods: I...

Du même sujet

Proteolytic activity of Lactobacillus strains isolated from Mongolian tradi...

Archive ouverte: Article de revue

Raveschot, Cyril | 2020-01-30

Le Réseau Mixte Technologique Sols et Territoires : développer la connaissa...

Archive ouverte: Article de revue

Guellier, Camille | 2014

absent

Soil bioindicators: how soil properties influence their responses and to se...

Archive ouverte: Communication dans un congrès

Pauget, Benjamin | 2015-05-03

International audience

Les incitations financières à la réalisation d’objectifs comportementaux li...

Archive ouverte: Article de revue

Crainich, David | 2022-02

International audience. Les programmes octroyant des récompenses pécuniaires aux individus qui parviennent à atteindre un objectif lié à la santé (arrêter de fumer, perdre du poids, etc.) ont pour but de favoriser l...

Transcriptome assembly and abiotic related gene expression analysis of date...

Archive ouverte: Article de revue

Rekik, Imen | 2019-11-30

Characterization of free exopolysaccharides secreted by Mycoplasma myco...

Archive ouverte: Article de revue

Bertin, Clothilde | 2013

International audience. Contagious bovine pleuropneumonia is a severe respiratory disease of cattle that is caused by a bacterium of the Mycoplasma genus, namely Mycoplasma mycoides subsp. mycoides (Mmm). In the abs...

Chargement des enrichissements...